Friedberg Ezra M 4

What Happened
Ezra M. Friedberg, a director of Pelthos Therapeutics, reported open-market sales of a total of 558 shares of Pelthos common stock on July 2, 2026, generating roughly $14,556. The sales were disposals: 534 shares at a weighted-average price of $26.03 ($13,900) and 24 shares at a weighted-average price of $27.33 ($656). These sales were made pursuant to a Rule 10b5-1 plan and were described as being for the purpose of satisfying estimated tax obligations tied to the vesting of restricted stock units.

Key Details

• Transaction dates: July 2, 2026 (reported on Form 4 filed July 7, 2026). The filing appears to be late relative to the typical 2-business-day Form 4 deadline.
• Sale breakdown: 534 shares at a $26.03 weighted-average (multiple trades ranged $25.58–$26.24); 24 shares at a $27.33 weighted-average (trades ranged $27.20–$27.63). Reported total proceeds ≈ $14,556.
• Reason/footnote: Sales executed under a Rule 10b5-1 plan adopted December 16, 2025, to satisfy estimated tax obligations from RSU vesting (footnote F1).
• Beneficial ownership note: Friedberg is manager of Balmoral Financial Group LLC and Key Recovery Group LLC and may be deemed to beneficially own shares held by those entities; he disclaims such ownership except to the extent of pecuniary interest (footnote F4).
• Shares owned after the transaction: Not specified in the provided filing excerpt.

Context

• This was a sale (not a purchase); sales under pre-established 10b5-1 plans are common for tax or diversification reasons and do not necessarily indicate a change in insider sentiment about the company.
• The filing shows the reported prices are weighted averages across multiple trades; the filer offers to provide full trade-level details on request (footnotes F2 and F3).
• The reported filing date is July 7, 2026 for a July 2 transaction; delayed filings can be noted by investors but do not by themselves indicate company performance.